A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC
A Comparator Study of a Tasso Device to Traditional Venous Blood Sampling Methods for Complete Blood Count (CBC) With 5-part Differential in Patients With Leukemia, Lymphoma, and/or Other Blood Cell Disorders
Sponsor: Tasso Inc.
A observational or N/A phase clinical study on Leukocytosis and Leukopenia, this trial is actively recruiting participants. The trial is conducted by Tasso Inc. and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.
This investigation will include a minimum of 40 sample sets from unique patients.
The primary aim of this study is to demonstrate the agreement between capillary blood collected using the Tasso device and venous blood collected in a K2EDTA (dipotassium ethylenediaminetetraacetic acid) tube according to established sampling procedures for quantification of WBC and ANC as part of a standard CBC panel with 5-part differential.
The secondary aim of the study is to demonstrate the agreement between Tasso device and venous samples for the measurement of additional analytes evaluated as part of a standard CBC panel with 5-part differential, including PLTs, HGB, RBC, Hct, MCV, lymphocytes, monocytes, eosinophils, and basophils.
An exploratory aim of this research is to evaluate patient acceptance of the Tasso device in a diseased population.
Adverse Events (AEs) occurring up to 24 hours after use of the Tasso device will be evaluated.
Patient response to using the Tasso device will be collected via simple survey.
This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.
This investigation will include a minimum of 40 sample sets from unique patients.
The primary aim of this study is to demonstrate the agreement between capillary blood collected using the Tasso device and venous blood collected in a K2EDTA (dipotassium ethylenediaminetetraacetic acid) tube according to established sampling procedures for quantification of WBC and ANC as part of a standard CBC panel with 5-part differential.
The secondary aim of the study is to demonstrate the agreement between Tasso device and venous samples for the measurement of additional analytes evaluated as part of a standard CBC panel with 5-part differential, including PLTs, HGB, RBC, Hct, MCV, lymphocytes, monocytes, eosinophils, and basophils.
An exploratory aim of this research is to evaluate patient acceptance of the Tasso device in a diseased population.
Adverse Events (AEs) occurring up to 24 hours after use of the Tasso device will be evaluated.
Patient response to using the Tasso device will be collected via simple survey.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tasso Inc.
- The Leukemia and Lymphoma Society
For direct contact, visit the study record on ClinicalTrials.gov .